• A study published in 2020 showed that 100% of Red-tailed Hawks that were admitted to the Tufts Wildlife Clinic tested positive for the presence of rodenticides
• Given how rodents remain a crucial food source for birds of prey, anticoagulant rat poison is threatening these populations
• SenesTech, a rodent fertility control product provider, and the inventor of the only EPA-registered contraceptive for male and female rats, offers a much safer alternative
• The company’s Evolve(TM) soft bait products for rats and mice have been scientifically proven to manage rodent infestations, while minimizing risk to human health or the larger environment
• This supports the well-being of birds of prey and other animals while proactively managing rodent pest populations

Back in 2020, a study published by Tufts Wildlife Clinic and Cummings School of Veterinary Medicine showed that 100% of the Red-tailed Hawks admitted into their clinic tested positive for rodenticides. Earlier this year, Flaco, a famous Eurasian eagle owl that lived in Central Park, was found dead. A necropsy would later reveal that he was exposed to four different second-generation anticoagulant rodenticides (“SGARs”). It shed light on the use of rodenticides for rodent population control and its impact beyond rodents and onto a broader ecosystem that includes birds and other animals (https://ibn.fm/m6wJW).

SenesTech (NASDAQ: SNES), a rodent fertility control product provider and inventor of the only EPA-registered contraceptive for male and female rats, has addressed adverse safety and environmental issues of poisons through the use of non-lethal methods of rodent population control. Its flagship product line, Evolve(TM) soft baits for rats and mice, has been scientifically proven to manage rodent infestations while posing none of the known risks (https://ibn.fm/z3McO).

The company’s approach has been lauded for its sustainability and overall effectiveness, with various state governments adopting it to address their infestation problems.

“Rat birth control is a promising non-toxic solution to remediating heavily infested areas without dumping lethal poisons all over our city’s streetscape,” noted Shaun Abreu, an Upper West Side City Council Member (https://ibn.fm/4RvGK).

Anticoagulant rat poison, which is widely used, helps deal with the rat population by disrupting their blood clotting process. This usually results in internal bleeding, with rats becoming lethargic and weak, often having to deal with a significant amount of pain and discomfort before ultimately dying from organ failure or blood loss (https://ibn.fm/uLFS7).

When predators consume these poisoned animals, they also consume the poison, and after that, they experience the same symptoms as the rats. In the last two years alone, 43 red-tailed hawks admitted have tested positive for anticoagulant rodenticides. For an endangered species such as the bald eagle, using these rodenticides threatens to undo decades-long efforts to protect such species.

“We have no choice but to remove these poisons from the environment,” noted Lla Anderson of Harvard’s Animal Law & Policy Clinic. “We have got to stop feeding them to rodents,” she added.

SenesTech’s Evolve(TM) products are more sustainable, non-lethal to the broader ecosystem, and more effective than alternatives currently in the market. The active ingredient in the product, Cottonseed Oil, has been proven to interfere with the reproductive mechanisms in both male and female rodents, ultimately targeting infestation at its source. Results can be seen in 4-6 weeks, and the product could potentially eliminate the entire rodent population in an area within 12 to 18 months.

As the conversation around humane and non-lethal approaches to rodent population control continues to proliferate, SenesTech’s products continue to get a positive reception and an even wider adoption. The company continues to carve out a decent market share and stamp its position as a leader in the market. Most importantly, it continues to affirm its commitment to improving people’s quality of life by sustainably dealing with rodents.

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

• Correlate Energy, a publicly traded distributed energy solutions company, has made clean energy adoption as easy and as seamless as possible for the worldwide business community
• Doing so has allowed it to make a name for itself and carve out a decent market share in the growing renewable energy space
• With the global solar capacity set to reach 5.1 TW by 2028, Correlate is positioning itself strategically to tap this growth by making the transition easier and more affordable

According to Solar Power Europe, it is projected that in 2024, global solar capacity will reach 2.2 TW, up from 1.6 TW in 2023. It is further projected that in 2028, this number will hit 5.1 TW, mainly aided by the dropping cost of solar panels and associated costs linked to their installation. In addition, the growing positive reception of renewable energy by the masses is resulting in a growth in the adoption of solar energy, a trend that is set to continue as time progresses (https://ibn.fm/9N0LI).

One company that looks to capitalize on this trend is Correlate Energy (OTCQB: CIPI), a publicly traded company strategically positioned to capitalize on America’s unstoppable trend toward decentralized energy generation. With its unique market positioning, Correlate facilitating the global solar energy transition, offering important additional benefits associated with its adoption, encouraging profitability and overall sustainability while reducing carbon footprint.

So far, Correlate has developed, financed, and deployed over $2 billion in clean energy projects, a testament to the interest in its sustainable energy solutions. The company has achieved this by establishing decentralized systems, building and selling localized clean energy solutions and microgrids for industrial, commercial, and residential customers. Its approach has seen its products and services adopted throughout the United States, with notable customers including Safeway, Samsung, Cisco, Marshall Medical Center, and Tyson (https://ibn.fm/ZyE2n).

Correlate has grown its client list by making clean energy adoption as easy and seamless as possible. Joining its program is as simple as a company or individual opting in its facilities and providing 12 months of utility bills. Correlate’s end-to-end solution delivery also allows it to stand out from the rest, covering all aspects from solution origination to asset optimization, processes that most competitors in the market do not cover.

With Correlate, customers enjoy net operating income (“NOI”) gains of $0.50 to $5.00+ per square foot and $50,000 to $500,000 in annual NOI for a 100,000-square-foot building. In addition, the company promises to help customers achieve their stated Environmental, Social, and Governance (“ESG”) goals within their intended timeframe (https://ibn.fm/T7dFg).

Correlate has demonstrated its commitment to helping companies, big and small, transition to renewable energy, specifically solar power. Its efforts thus far reflect the extent it is willing to go to help companies realize their ESG and sustainability goals and objectives. More importantly, the company and its management recognize the opportunity in the renewable energy space and look to carve out a decent market share, ultimately stamping its position as a leader in its space.

For more information, visit the company’s website at www.Correlate.Energy, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.Correlate.Energy/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.Correlate.Energy/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

Toronto, July 22, 2024 – Canada Crypto Week, a week-long series of Web3 and AI events, is set to take place from August 11-17, 2024 in Toronto, Canada.

Blockchain Futurist Conference serves as the anchor event for Canada Crypto Week, providing a central hub for the majority of the week’s activities. Many of the 20+ events during Canada Crypto Week will take place onsite at the conference, offering attendees an interactive and immersive experience. Events include book signings, workshops, networking opportunities, the ETHToronto & ETHWomen Hackathon Experience, and more. This integration ensures that participants can fully engage with the majority of diverse offerings of Canada Crypto Week in one convenient location, encouraging collaboration within the Web3 community.

This highly anticipated week aims to highlight Canada’s significant contributions to the blockchain and cryptocurrency industry. Ethereum was born in Toronto, and the city boasts a huge tech community, with blockchain programs in its universities and a vibrant ecosystem of innovation. This week is a testament to Canada’s position as a major player in the global crypto landscape.

The official registrations for Canada Crypto Week are all utilizing blockchain technology. All tickets are on-chain on the METIS blockchain, an Ethereum Layer 2, utilizing the Web3 ticketing platform BlockLive.

Here’s a glimpse of a few of the events part of Canada Crypto Week:

LTD Boat Party
August 13 @ 6:30 PM – 10:00 PM
Dockside at Futurist Conference 

Crypto Ecosystem Night by VirgoCX
August 12 @ 5:00 PM – 11:00 PM
One King West Hotel & Residence

Blockchain Bootcamp
August 13 @ 10:00 AM – 12:00 PM
Purple Room at Futurist Conference

Talent Pool Games by TeamSpark
August 13 & 14 @ 10:00 AM – 5:00 PM
Poolside at Cabana Pool Bar at Futurist Conference

ETHToronto Hackathon
August 13 & 14 @ 8:00 AM – 6:00 PM
Upstairs at Futurist Conference 

ETHWomen Experience
August 13 & 14 @ 8:00 AM – 6:00 PM
Upstairs at Futurist Conference 

Newton VIP Event
August 14 @ 2:00 PM
Purple Room at Futurist Conference – Invite Only  

Women’s Breakfast
August 14 @ 9:00 AM – 12:00 PM
Level 2, Futurist Conference

Kids AI, Web3 & Robotics
August 14 @ 9:30 AM – 10:30 AM
Purple Stage at Futurist Conference

Artificial Intelligence @ Futurist Conference
August 14 @ 9:00 AM – 3:00 PM
Futurist Conference

AWIC Facilitated Networking @ ETHWomen
August 14 @ 11:30 AM – 12:45 PM
Level 2, Futurist Conference

Startup Investor Drinks by Toronto Starts
August 14 @ 6:00 PM – 8:30 PM
Workhaus, 30 Wellington Street West

Book Signing with Author Alex Tapscott: Web3: Charting the Internet’s Next Economic and Cultural Frontier
August 13 @ 12:00 pm – 12:45 pm
Presentation on Main Stage & Main Floor Expo Hall

Book Signing with Author Ari Juels: The Oracle: A Novel
August 14 @ 12:00 pm – 12:45 pm
Main Futurist Stage & Level 1 Expo Hall

Book Signing with Author Annelise Osborne: From Hoodies to Suits: Innovating Digital Assets for Traditional Finance
August 14 @ 2:00 pm
Main Floor Expo Hall, Toronto

New events are frequently being added to Canada Crypto Week and organizers encourage all interested parties to register ASAP to secure their spots.

To see full list of events, register or submit your own event, go to  https://www.canadacryptoweek.com

To purchase tickets to Blockchain Futurist Conference, go to https://www.futuristconference.com/

FinovateFall 2024 invites investors, insurers, directors, and C-level executives from banks, for two days of networking, discussions, and a fintech showcase at the prestigious Marriott Marquis Times Square, New York. Finovate has been serving the fintech fraternity for over 15 years, spotlighting fintech companies from startups to veterans on a robust networking platform where they can discuss and demo innovative business strategies.

Discover and explore the latest trends, strategies, and innovative offerings as world leaders, top banks, notable investors, and decision-makers of the fintech community share their knowledge and ideas at the FinovateFall 2024 in New York. Over 120 eminent dignitaries will preside as speakers discussing the latest fintech and financial services. They will share their valuable insights into the future of financial services across the globe.

Top investment firms, including asset/investment managers and family offices, and 18 out of 20 top US banks, have confirmed their presence at this major Finovate event. This represents a singular opportunity for newbies to connect with investors and banks to help move their business forward.

The Finovate community works to foster business relationships with the industry players and create conducive environments for networking and collaborations. About 2,000+ veteran decision-makers, of which 1,000+ are banks & investors, will attend the event, sharing their invaluable expertise.

The FinovateFall team has scheduled a vast number of meetings where businesses and investors can connect on a one-to-one basis. Young companies, new unicorns, and seasoned fintech leaders, will stage demos to showcase their unique products and services. The 60+ product demos will be presented on the stage paired with demo stalls in the expo hall.

FinovateFall also runs the Fintech Scholarship Program that focuses on fintech companies that drive social and environmental changes.

To know more, please visit https://ibn.fm/5x9bn

• MedCana has identified Colombia’s Antioquia Valley as a perfect location to begin its initial rollout of technology and production
• The company is working with five subsidiaries in the area, each of which has three licenses to produce, process and export cannabis
• Equally important to MedCana is working closely with the people of the Antioquia Valley and maintaining its commitments to its investors

Cannabis legalization is not exclusive to North America. So far, more than 40 countries have legalized cannabis fully or partially for medical and/or adult use (https://ibn.fm/TdZkM). With its focus on the global horizon, Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) has a vision of building its partner companies into one of the world’s most advanced cannabinoid production and processing organizations.

MedCana has taken the first step in achieving that global mission. Recognizing that ideal climate conditions produce a better yield, the company announced that it has “searched the world over, and we believe the Antioquia Valley, near Medellin [Colombia], is the perfect location to begin our initial rollout of technology and production. We are partnering with companies [in the valley] to begin implementation of our technology and tools with our partners.

“The 6,900-foot elevation and latitude provide optimal spring-like weather year-round,” the announcement continued. “Natural rainfall and multiple artesian springs mean perfect, clean water. The soils are rich, and combined with the long days of sunshine, we can complete four complete growth cycles per year. This means access to highest-quality, inexpensive, certified materials in order to produce the highest-grade pharmaceutical extracts needed by the top pharmaceutical companies in the world” (https://ibn.fm/hPFWt).

MedCana is working with five subsidiaries, each of which has three licenses to produce, process and export cannabis. Currently, the five companies are sharing 100 acres of some of the “finest land on earth” for development; the property includes fresh artesian springs, river frontage and majestic countryside.

On top of ideal outdoor growing conditions, MedCana companies are also building greenhouses to take full advantage of all the climate offers. The first phase of production includes an estimated seven acres of initial greenhouse space combined with state-of-the-art monitoring technology and highly trained staff.

“Because of excellent weather, long days and highly skilled, inexpensive labor, costs decrease dramatically,” the company reports. “An average of 12 hours of sunshine every day, perfect local soils, and plentiful rain and natural springs mean we’ll be able to grow up to four full seasons per year without the cost of expensive and power-hungry lighting.”

However, MedCana isn’t singularly focused on profit. Equally important to the company is working closely with the people of the Antioquia Valley and maintaining its commitments to its investors. “MedCana is out to prove you can do good and do well,” the company promises. “Our initial partnership in the Antioquia Valley operation will employ people from the local villages and pay some of the best salaries for agricultural trades in the country. In addition, MedCana will give back to the local communities to improve the lives of the residents. Schools, clinics, and civic projects will all benefit from our operation.

“And by doing good, we’ll do well,” the company continues. “Even with the high local salaries, our partner companies will be operating at costs far lower than in the United States, Europe and Asia. We estimate that all our efficiencies will result in a lower price of finished, top-quality, pharmaceutical grade CBD oil, [with costs] dramatically lower than production in the Northern Hemisphere.”

For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://ibn.fm/SFWJ

• Lexaria, a global innovator in drug delivery platforms, has released interim results from its WEIGHT-A24-1 animal study
• The study sought to explore the impact of its patented DehydraTECH technology on glucagon-like peptide-1 (“GLP-1”) drugs for the potential treatment of diabetes and weight loss, representing a major global market
• The first 28 days of dosing yielded positive results that Lexaria’s management described as “noteworthy”
• It also marked a significant milestone for the company and the first time it has used liraglutide in any of its GLP-1 studies

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery enhancement, just released interim results from its WEIGHT-A24-1 animal study. The study evaluated the company’s patented DehydraTECH technology and its potential to address diabetes and weight loss. The first four weeks of dosing was successful, with Lexaria’s management describing its findings as “noteworthy” (https://ibn.fm/lfgm7).

The first phase of this study involved eight study arms, four of which used varying compositions of DehydraTECH-processed CBD. Two of the arms used reformulated Rybelsus(R) composition, which included DehydraTECH and sodium salcaprozate (“SNAC”) technology. In contrast, the last two used pure GLP-1 drugs, primarily semaglutide and liraglutide, respectively, without SNAC inclusion. This marked the first time Lexaria has used liraglutide in any glucagon-like peptide-1 (“GLP-1”) study.

“This is the first time that DehydraTECH processing was applied to the GLP-1 drug liraglutide, and it is encouraging to witness its relative outperformance,” noted Lexaria’s official reporting on the findings.

Over the course of the study, unlimited food and water were provided to the animals. In the initial acclimation phase, 34 days before the beginning of dosing, the animals gained 10.9% body weight on average. During the subsequent 28 days of dosing, all animals showed either a noticeable decrease in the rate of body weight gain or the beginning of weight reduction. Most notably, DehydraTECH-liraglutide and DehydraTECH-CBD produced the most significant weight loss results at -1.58% and -1.50%, respectively.

For Lexaria, this marks a significant milestone, not just with using liraglutide in its studies but also in closing the first eight study arms and evaluating results from the first 28 days of dosing. An additional 56 days of dosing remains across all treatment groups.  Its management is optimistic about upcoming results, with the confidence that the progress achieved will be integral in shaping the outcome of future studies.

Dosing for Cohort 2 of the study has already begun and is expected to be completed in mid-October. This Cohort will feature four study arms, including a positive control arm, a placebo arm, a combined DehydraTECH-semaglutide with DehydraTECH-CBD arm, and a combined DehydraTECH-liraglutide with DehydraTECH-CBD.

This study affirms the company’s focus on both medium-term and longer-term strategies. Its management is optimistic about this undertaking and looks to follow through with it within its set timelines.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• In 2022, Canadian mines produced 510,782 tonnes of copper in concentrate, with over half originating from British Columbia
• The Quesnel Terrane, which is home to Torr Metals’ expansive Kolos Copper-Gold Project, has the potential to be instrumental in Canada’s next great copper discoveries
• Torr’s recent rock sampling confirmed copper porphyry mineralization in outcrop adjacent to Highway 5 in the heart of the southern Quesnel Terrane, with assays returning economic values as high as 4,240 ppm Cu and 1.07 g/t Au

Canada stands as a global mining titan, amidst British Columbia becoming the largest copper producer, commanding 53% of total Canadian production and generating 510,782 tonnes in 2022. Renowned for its epic gold rushes and legendary mining camps, many of which still thrive, Canada’s mining history is the stuff of legends.

With vast, unexplored territories surrounding existing mines, the potential for groundbreaking new discoveries is immense. The Quesnel Terrane and companies like Torr Metals (TSX.V: TMET) exemplify this exciting frontier.

The future is undeniably promising. The vast expanse of highly prospective, unexplored terrain surrounding both existing and historical mines paves the way for new discoveries that could potentially rival or even surpass those of the past centuries.

The Quesnel Terrane: A Geological Treasure Trove

The Quesnel Terrane, spanning British Columbia and Yukon, boasts a complex geological landscape shaped by millions of years of tectonic collisions and volcanic activity. This region, rich in natural resources, has a storied past highlighted by events like the Cariboo Gold Rush, underscoring its significant economic potential.

Rich in gold, copper, molybdenum, and coal, the Quesnel Terrane continues to captivate geologists and explorers alike. Its intricate geological history has created a diverse mineral landscape, offering promising opportunities for new discoveries. Some notables in the Quesnel include the New Afton copper/gold mine, Highland Valley (Canada’s largest open pit copper and molybdenum mine), and Mount Milligan, a large-scale copper and gold mine, to name a few.

As the world increasingly demands critical minerals for clean energy technologies, including copper, the Quesnel Terrane’s potential to supply these essential elements grows even more significant.

Poised to Capitalize

One company poised to capitalize on the region’s promise is Torr Metals. Their 100% owned Kolos Copper-Gold Project, spanning 240 square kilometers within the Quesnel Terrane, is a prime example of the area’s exploration and expansion potential. The project benefits from excellent infrastructure and proximity to established mining operations, while being just 286 kilometers by highway northeast of the city and port of Vancouver.

With multiple underexplored copper and gold occurrences, the Kolos project represents a compelling opportunity for significant new discoveries. Torr Metals’ recent expansion of the project area and the discovery of new mineralized zones further highlight the region’s prospectivity.

Last month, final assay results were released from the 2023 rock sampling program together with the delineation of a robust ZTEM geophysical anomaly at the newly defined Vik Zone, within the eastern portion of the Kolos project. Out of 47 rock grab samples assayed, 22 yielded >100 ppm Cu (parts per million copper) with 9 samples >500 ppm Cu. The highest value returned 4,240 ppm Cu. A total of 8 rock grab samples returned >0.1 g/t Au (grams per tonne gold) with 2 samples >0.2 g/t Au; the highest value was 1.07 g/t Au.

The Vik Zone at Kolos has sparked significant interest as a previously unknown grassroots discovery. This new find, featuring copper and molybdenum mineralization, is situated at the edge of one of three promising but completely unexplored underground resistivity zones that extend along a 2.5 kilometer trend. With the discovery of the Vik Zone validating Torr’s methodical exploration approach and only 30% of the Kolos Project explored, the pressing question remains: how much more potential lies within?

Looking ahead, Torr Metals has completed an initial reconnaissance field sampling program in 2024, covering newly acquired areas to the north and east. Assays for 27 outcrop and float rock grab samples are pending, and investors eagerly await details of this program.

Torr Metals’ story isn’t just about copper discovery at Kolos; it’s also about the significant gold potential in northern Ontario. Just as Kolos promises to be transformative for the Quesnel, Torr Metals’ 261 km2 Filion Gold Project could have a major impact on Ontario’s rich mining history. Strategically positioned amid abundant infrastructure and existing mines, Filion is set for extensive exploration following the recent securing of a three-year exploration permit.

Back to Quesnel: The Next Great Copper Frontier

With advancements in exploration technologies and a deepening geological understanding of the Quesnel Terrane, the potential for groundbreaking discoveries is increasingly within reach. This geological province offers a glimpse into Earth’s past and stands as a promising frontier for the future of mining and resource development, presenting substantial opportunities for investors to capitalize on new and significant resource finds.

For more information, visit the company’s website at www.TorrMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to TMET are available in the company’s newsroom at https://ibn.fm/TMET

• Distributed energy solutions developer Correlate Energy Corp. helps clients find an affordable way to step up their energy use infrastructure through retrofit upgrades, taking advantage of a variety of financial incentives
• Decentralized energy generation has been trending as groups throughout the country search for ways to reduce carbon emissions and secure their power supply amid utility outages
• Correlate’s success is evident in its growing list of project fulfillments and growing revenue targets — $45 million to $60 million with 25 percent gross margins this year
• The company is working to uplist to the New York Stock Exchange, using a $7 million IPO to help launch its effort

A combination of unprecedented levels of government incentives and growing private sector investment funding are pushing a noteworthy shift in energy trends as decentralized electrical energy generation gains an increasing following, according to an MSE Investments report praising the visionary qualities of Correlate Energy (OTCQB: CIPI).

The distributed energy solutions company recently announced its coming role in co-developing the nation’s first microgrid utility based on four interconnected microgrids costing about $400 million and serving commercial, industrial, and eventually government and community loads (https://ibn.fm/E8fUU).

Decentralized energy generation — that is, the establishment of self-sufficient energy systems that are capable of working independently of the larger central power grid in delivering energy to small, specific geographic locations such as university campuses, business complexes or certain residential neighborhoods — is growing not only because of the financial incentives from public and private sectors, but also because of growing interest in environmentally friendly “renewable” energy sources, the incapacity of central grids in certain areas to build the infrastructure necessary to serve all of the area’s residents, and frustrations with some central grids’ power outage problems, according to the MSE Investments report.

“Fortunes can be made when energy trends radically shift. And today we stand at the beginning stages of a burgeoning, unstoppable trend in America towards decentralized electrical energy generation. This trend is exponentially increasing current by the kilowatt hour with no foreseeable diminishment,” the report states (https://ibn.fm/wAPUy).

Correlate Energy Corp. projects its revenues this year will be in the range of $45 million to $60 million with 25 percent gross margins, an improvement over last year’s revenue targets. The company is further preparing for revenue growth by working to uplist from the OTCQB exchange to the New York Stock Exchange.

The company plans to raise $7 million through a planned initial public offering (“IPO”) to help fund the move to the NYSE (https://ibn.fm/eaS8L).

“2023 was all about executing what we started the year prior. … This is all about maturing the backlog of projects we have, and we’re now starting to see those revenues occur,” Correlate President and CEO Todd Michaels said during a Proactive Investors interview at the end of the year (https://ibn.fm/qpRtI). “It’s been all about executing on what we had in (2022) and setting ourselves up for doubling again, tripling again in the coming year. … The fact that we have this constant conveyor belt of maturity of opportunities really allows us to smartly invest in different parts of the business from origination and sales to construction and oversight.”

For more information, visit the company’s website at www.Correlate.Energy, including the following:

Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.Correlate.Energy/our-process
Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.Correlate.Energy/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• Annovis announced in June 2024 that they had filed a composition of matter patent for their new crystal form of buntanetap, along with a provisional patent for the manufacturing process
• The company’s goal is to use this technology to restore brain function and improve the quality of life for patients dealing with neurodegenerative disease such as Alzheimer’s disease
• The worldwide market for Alzheimer’s disease modifying drugs, versus symptomatic drugs, could approach $30 billion by 2030

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders like Alzheimer’s and Parkinson’s, just announced that the U.S. Food and Drug Administration (“FDA”) has given approval for Annovis to switch to a new solid form of buntanetap for their future clinical trials (https://ibn.fm/KfHve).

In June 2024, Annovis announced they had filed a composition of matter patent for their new crystal form of buntanetap, along with a provisional patent for the manufacturing process. To reach this milestone, they conducted extensive bridge studies comparing the old semi-crystalline form with the new crystalline form in various solvents and animals. Additionally, they developed an innovative large-scale manufacturing process for the new form and submitted all this data to the FDA for review.

In a previous press release, Maria Maccecchini, Ph.D., Founder and President of Annovis said the invention of a new solid form of buntanetap and the subsequent patent filing represent groundbreaking milestones for the company. “This achievement will allow us not only to continue advancing our pipeline, but also to enhance the drug’s properties, ultimately providing greater benefits to our patients,” Maccecchini added.

With the FDA’s approval, Annovis can now move forward with their plans. They will conduct a small, single-dose study in humans to compare the old and new forms of buntanetap and assess their effectiveness.

According to a Fortune Business Insights report, the global Alzheimer’s drugs market size was valued at USD 3.52 billion in 2022 and is projected to grow from USD 3.69 billion in 2023 to USD 5.21 billion by 2030, exhibiting a CAGR of 5.1% during the forecast period (https://ibn.fm/DXKAV). However, for actual Alzheimer’s disease modifying drugs, versus symptomatic drugs, the worldwide market could approach $30 billion by 2030.

Buntanetap, known as Posiphen, is Annovis Bio’s leading candidate in the fight against neurodegeneration. It works by blocking the production of several neurotoxic proteins – amyloid beta, tau, alpha-synuclein, and TDP43. These proteins can cause significant issues for nerve cells, including impaired synaptic transmission and axonal transport, neuroinflammation and cell death.

By targeting these harmful proteins, buntanetap aims to reverse the damage caused by neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The goal is to restore brain function and improve the quality of life for patients facing these challenging conditions.

“As we continue to advance our pipeline, securing our manufacturing rights for new forms of buntanetap is vital,” said Michael Christie, Ph.D., Vice President of Process Chemistry. “This ensures we maintain control over the production process, protect our intellectual property, and continue our mission to deliver novel therapeutics for patients suffering from neurodegenerative disorders.”

Annovis Bio is dedicated to improving the lives of patients with neurodegenerative diseases. Their mission is to find ways to slow down, stop, or even reverse the progression of these diseases. They are in the late stages of developing new therapies that could be transformative for patients and their families. With the FDA’s latest approval, Annovis is one step closer to bringing their innovative treatments to those in need.

For more information, visit the company’s website at www.AnnovisBio.com, and social channels
LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

• Cost-effective and recidivism-reducing alternatives to incarceration continue to occupy a priority for criminal justice systems worldwide as societies grapple with balancing concerns ranging from minimizing threats to sustaining positive work and family environments
• During the past four decades, electronic monitoring has emerged as a way to help individuals continue functioning positively within their communities after they have been convicted of criminal behavior
• Israel-based SuperCom Ltd. is positioning itself to be competitive in a field of related government-ordered service contracts, developing a suite of secure identification and digital monitoring products as an end-to-end solution for electronic monitoring programs
• The company is gaining prominence and has announced over $11 million in European government contract orders since April

The use of electronic monitoring (“EM”) to track the whereabouts of domestic violence or other offenders has risen steadily over the last 40-plus years since the state of Florida’s Department of Corrections became the first criminal justice administration to experiment with EM and then adopt it as a way to reduce prison overcrowding and related costs (https://ibn.fm/iqj6C).

The prevalence of domestic violence worldwide and growing efforts to address it have been a significant driver of such attempts to reform incarceration programs while establishing safety measures for the public if an offender is not incarcerated ((https://ibn.fm/FZKNU).

Technological devices used in the dozens of countries where EM is now common have varied over time, including radio-frequency pagers as well as satellite-connected GPS system ankle bracelets and wrist bands (https://ibn.fm/Lh04u).

Electronic monitoring technology innovator SuperCom (NASDAQ: SPCB) is delivering next-level solutions to the EM market through its Puresecurity suite of hardware, connectivity, and software components.

SuperCom serves governments and private organization clients worldwide, with a particular focus on the market in the United States but bolstered by $11 million in new orders from European government clients since April (https://ibn.fm/YcoDe).

The technology also has the capacity to serve a wide range of applications that are not based in criminal justice, such as tracking Alzheimer’s patients prone to wander or vulnerable patients with no in-residence caregiver. However, its primary application at present is monitoring offenders for criminal justice systems, including domestic violence-related cases and substance abuse rehabilitation.

During an interview with the Your Advantage Play podcast earlier this month, SuperCom President and CEO Ordan Trabelsi indicated that the company prefers to focus on one application at a time and expand into new opportunities organically (https://ibn.fm/EHcHN). The offender monitoring market is a niche sector with relatively few developed competitors, presenting SuperCom with greater opportunities to show how its product stands out and to generate revenue.

“If you look at Europe, for example, where we started off with small projects for $100,000, $200,000 in size, now we’re running into projects that are $5 (million), $7 (million) and even $30-plus million in size,” Trabelsi said. “And that just shows how sometimes the market dynamics and the industry have to match your offering, so you can make a disruptive change in the industry and also for your company.”

Unfortunately, bulky ankle monitors continue to be commonly prescribed by legislation and courts in response to domestic violence cases in which threat assessments are narrowly focused (https://ibn.fm/yz7rG), and the challenges of administering such programs require ongoing attention and flexibility in designing EM plans (https://ibn.fm/Y1iGu). However, SuperCom’s wearable EM device has the advantage of being virtually unnoticeable underneath clothing, reducing unnecessary stigmatization of monitored subjects at work and in other public environments.

The company’s Puresecurity suite’s IoT product line uses artificial intelligence capability to amplify user decision-making ability through data analysis and predictive modeling. And the base technology has the advantage of long battery life in lightweight packaging, which allows it to be durable and versatile.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB